Ghosh D

No ORCID on file · 12 papers in corpus · active 2011-2025

Study types

  • review 3
  • article 2
  • other 2
  • case-report 1

Condition tags

  • endometriosis 5
  • chronic_pelvic_pain 1
  • dysmenorrhea 1
  • endometrioma 1
  • die_deep_infiltrating 1
  • dyspareunia 1
  • infertility 1
article 2025
Neurogastroenterology and motility ·doi:10.1111/nmo.70081

BACKGROUND/AIMS: Many patients with digestive symptoms describe underlying urinary or gynecologic symptoms, which may increase visceral sensitivity in the abdominopelvic region and amplify distress around digestive symptoms. The aim of this…

case-report 2024
Case reports in women's health ·doi:10.1016/j.crwh.2024.e00658

Benign multicystic peritoneal mesothelioma (BMPM) is a rare peritoneal tumour. Treatment involves complete surgical resection, although recurrence rates are high. Notably, there are 7 documented cases of BMPM coexisting with endometriosis o…

2024
Frontiers in cell and developmental biology ·doi:10.3389/fcell.2024.1423279

LncRNAs are RNA molecules of more than 200 nucleotides in length and participate in cellular metabolism and cellular responses through their diverse interactomedespite having no protein-coding capabilities. Such significant interactions als…

review 2023
Methods in enzymology ·doi:10.1016/bs.mie.2023.04.025

Cytochrome P450 aromatase (AROM) and steroid (estrone (E1)/dehydroepiandrosterone (DHEA)) sulfatase (STS) are the two key enzymes responsible for the biosynthesis of estrogens in human, and maintenance of the critical balance between androg…

other 2023
The Journal of steroid biochemistry and molecular biology ·doi:10.1016/j.jsbmb.2022.106228

Human placental estrone (E1)/dehydroepiandrosterone (DHEA) sulfatase (human placental steroid sulfatase; hSTS) is an integral membrane protein of the endoplasmic reticulum. This Ca2+-dependent enzyme catalyzes the hydrolysis of sulfate este…

review 2023
Steroids ·doi:10.1016/j.steroids.2023.109249

Cytochrome P450 aromatase (AROM) and steroid sulfatase (STS) are the two key enzymes for the biosynthesis of estrogens in human, and maintenance of the critical balance between androgens and estrogens. Human AROM, an integral membrane prote…

article 2020
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2020.05.008

Research questionDo endometrial stromal cells from primary infertile patients with severe ovarian endometriosis display differential secretory profiles of inflammation-associated cytokines during the implantation window that may cause infer…

2016
Journal of medicinal chemistry ·doi:10.1021/acs.jmedchem.5b01281

Human aromatase catalyzes the synthesis of estrogen from androgen with high substrate specificity. For the past 40 years, aromatase has been a target of intense inhibitor discovery research for the prevention and treatment of estrogen-depen…

2013
Journal of human reproductive sciences ·doi:10.4103/0974-1208.121424

BackgroundConflicting results were yielded about the superiority of gonadotropin-releasing hormone agonist (GnRH-a) versus gonadotropin-releasing hormone antagonist (GnRH-ant) protocols used in ovarian stimulation in in vitro fertilization …

other 2012
Reproductive biology and endocrinology : RB&E ·doi:10.1186/1477-7827-10-84

BACKGROUND: In order to obtain a lead of the pathophysiology of endometriosis, genome-wide expressional analyses of eutopic and ectopic endometrium have earlier been reported, however, the effects of stages of severity and phases of menstru…

2012
Journal of medicinal chemistry ·doi:10.1021/jm300930n

Human cytochrome P450 aromatase catalyzes with high specificity the synthesis of estrogens from androgens. Aromatase inhibitors (AIs) such as exemestane, 6-methylideneandrosta-1,4-diene-3,17-dione, are preeminent drugs for the treatment of …

review 2011
Fertility and sterility ·doi:10.1016/j.fertnstert.2010.05.021

OBJECTIVE: To determine the role of the aromatase inhibitor letrozole in the treatment of recurrent ovarian endometrioma cases. DESIGN: Nonrandomized proof of concept study. SETTINGS: Outpatient tertiary-care center. PATIENT(S): Five pre…